Evicenter
MarkdownMedical informationP&T meetings
Ersodetug (RZ358)

Tumor hyperinsulinism

Manufacturer
Rezolute
Launch
Not announced
Last updated
140 sources

Section 5 of 6

Economic information and modeling report

9 evidence topics · 6 sources

Modeling overview

Summary: published economic evidence and company market statements

  • The report holds no published cost-effectiveness analysis, health technology assessment, or analyst sales forecast for ersodetug in tumor hyperinsulinism. All economic statements come from the manufacturer.
  • The manufacturer's U.S. patient estimates use different measures: approximately 3,000 patients per year as the “immediately addressable incidence market” (Form 10-K), approximately 4,000 patients per year on the same measure (Form 10-Q), approximately 4,500 patients as the “total addressable market” (2024 release, which states that including NICTH would more than double the population), and about 2,500 malignant insulinoma and about 1,500 NICTH patients as a point-in-time prevalence as of October 2026 from the Veeva Compass claims database (October 2026 presentation).
  • The October 2026 presentation gives a tumor HI market of about 4,000 patients and a total addressable market of $4 to 5 billion, a combined U.S. opportunity of about 6,000 patients, and a global market opportunity of more than $5 billion.
  • Company payer research describes the indications as having low budgetary impact that supports ultra-rare disease pricing, and states likely payer acceptance of weight-based pricing. At a 9 mg/kg maintenance dose and an average adult weight of about 80 kg, the company assumes 9 vials per infusion and 117 vials per year per patient with infusion every four weeks.
  • The primary payer in the company's claims data was Medicare for 48.6% of patients, commercial insurance for 43.9%, Medicaid for 5.5%, and other payers for 2.0%.

Tumor hyperinsulinism payer mix in claims data

Published analyst sales forecasts for ersodetug in tumor hyperinsulinism

No evidence found.

Health technology assessments and published economic evaluations of ersodetug

No evidence found.

Budget impact model

Approach and framework

No evidence found.

Perspective and time frame

No evidence found.

Epidemiology and eligible population inputs

No evidence found.

Cost assumptions

No evidence found.

Model outcomes

No evidence found.

Results

Base case

No evidence found.

Scenario analyses

No evidence found.

Budget impact model discussion

Summary

No budget impact model for ersodetug in tumor hyperinsulinism has been published, and the manufacturer has published no price. The report holds the following inputs for one:

  • Eligible population: the manufacturer's U.S. estimates of approximately 3,000 patients per year (Form 10-K) or approximately 4,000 patients per year (Form 10-Q) as the immediately addressable incidence market, approximately 4,500 patients as the total addressable market (2024 release), and about 2,500 malignant insulinoma and about 1,500 NICTH patients as a point-in-time prevalence as of October 2026 (October 2026 presentation). Each figure describes a different measure.
  • Treatment setting: the manufacturer believes 60% of patients are managed at National Cancer Institutes and academic medical centers.
  • Drug use: the studied regimen is 9 mg/kg weekly for 8 weeks, followed by extension dosing every 2 to 4 weeks. The manufacturer assumes about 80 kg average adult weight, 9 vials per infusion, and 117 vials per year per patient with infusion every four weeks.
  • Payer mix: Medicare 48.6%, commercial 43.9%, Medicaid 5.5%, and other 2.0% of patients in the company's claims data.
  • Price: no wholesale acquisition cost or average sales price exists for the investigational product. The manufacturer's payer research describes expected ultra-rare disease pricing and weight-based pricing with reimbursement through a J-code.